Frontlight ResearchEarly access
TerminatedNo phase
LUNG INFECTION IN ICU (LUNG-I3)
Key facts
- Who runs it
- BioMérieux
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 7 people enrolled
- Started
- 5 Dec 2023
- Ended
- 25 Jun 2026
- Type of study
- Observational
- Record updated
- 30 October 2026
- Why it stopped
- Low recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- All the following criteria
- Age 18 years or greater
- Severe ICU patients hospitalized for one of the above diseases:; Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20); Severe trauma (level I and II), Injury Severity Score ≥ 25 OR; Burn with TBSA over 20%
- NAD > 0.1 µg/kg/min
- At least 2 SOFA criteria ≥ 2 points
Who cannot take part
- Immunocompromised patients, defined as; patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease; hematologic malignancies; solid organ transplantation; HIV infection with or without AIDS; treatment with corticosteroids (> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for > 7 day); treatment with other immunosuppressive drugs
- Aspiration pneumonia
- Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
- COPD
- Smoke inhalation in burn patients
- Participation in an intervention study
- Pregnant or breastfeeding women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- LUNG INFECTION IN ICU
- Record updated
- 30 October 2026